These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 22544005)

  • 41. Clock genes and body composition in patients with schizophrenia under treatment with antipsychotic drugs.
    Moons T; Claes S; Martens GJ; Peuskens J; Van Loo KM; Van Schijndel JE; De Hert M; van Winkel R
    Schizophr Res; 2011 Feb; 125(2-3):187-93. PubMed ID: 21050724
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Allelic variation in ApoC3, ApoA5 and LPL genes and first and second generation antipsychotic effects on serum lipids in patients with schizophrenia.
    Smith RC; Segman RH; Golcer-Dubner T; Pavlov V; Lerer B
    Pharmacogenomics J; 2008 Jun; 8(3):228-36. PubMed ID: 17726453
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.
    Stroup TS; Lieberman JA; McEvoy JP; Swartz MS; Davis SM; Capuano GA; Rosenheck RA; Keefe RS; Miller AL; Belz I; Hsiao JK;
    Am J Psychiatry; 2007 Mar; 164(3):415-27. PubMed ID: 17329466
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Diabetes risk associated with use of olanzapine, quetiapine, and risperidone in veterans health administration patients with schizophrenia.
    Lambert BL; Cunningham FE; Miller DR; Dalack GW; Hur K
    Am J Epidemiol; 2006 Oct; 164(7):672-81. PubMed ID: 16943266
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Insulin secretion in patients receiving clozapine, olanzapine, quetiapine and risperidone.
    Manu P; Correll CU; Wampers M; van Winkel R; Yu W; Shiffeldrim D; Kane JM; De Hert M
    Schizophr Res; 2013 Feb; 143(2-3):358-62. PubMed ID: 23231880
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparing tolerability profile of quetiapine, risperidone, aripiprazole and ziprasidone in schizophrenia and affective disorders: a meta-analysis.
    Moteshafi H; Stip E
    Expert Opin Drug Saf; 2012 Sep; 11(5):713-32. PubMed ID: 22913713
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Rate of new-onset diabetes among patients treated with atypical or conventional antipsychotic medications for schizophrenia.
    Ollendorf DA; Joyce AT; Rucker M
    MedGenMed; 2004 Jan; 6(1):5. PubMed ID: 15208518
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Metabolic syndrome in drug-naïve first-episode psychosis treated with atypical antipsychotics.
    Sahoo S; Ameen S; Akhtar S
    Aust N Z J Psychiatry; 2007 Jul; 41(7):629. PubMed ID: 17691161
    [No Abstract]   [Full Text] [Related]  

  • 49. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
    Krzystanek M; Krupka-Matuszczyk I
    Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Weight gain, obesity, and metabolic indices following a first manic episode: prospective 12-month data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM).
    Bond DJ; Kauer-Sant'Anna M; Lam RW; Yatham LN
    J Affect Disord; 2010 Jul; 124(1-2):108-17. PubMed ID: 19914720
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A prospective study of glucose homeostasis in quetiapine-treated schizophrenic patients by using the intravenous glucose tolerance test.
    Chen CH; Lin TY; Chen TT; Chen VC; Lin NC; Shao WC; Lu ML
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun; 35(4):965-9. PubMed ID: 21291941
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacy cost evaluation of risperidone, olanzapine, and quetiapine for the treatment of schizophrenia in acute care inpatient settings.
    Mladsi DM; Grogg AL; Irish WD; Lopez RB; Degen K; Swann A; Nimsch CT
    Curr Med Res Opin; 2004 Dec; 20(12):1883-93. PubMed ID: 15701206
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A comparative pilot study of second-generation antipsychotics in children and adolescents with schizophrenia-spectrum disorders.
    Jensen JB; Kumra S; Leitten W; Oberstar J; Anjum A; White T; Wozniak J; Lee SS; Schulz SC
    J Child Adolesc Psychopharmacol; 2008 Aug; 18(4):317-26. PubMed ID: 18759641
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Serum prolactin, leptin, lipids and lipoproteins levels during antipsychotics treatment in Parkinson's disease and related psychosis.
    Rustembegovic A; Sofic E; Wichart I
    Med Arh; 2006; 60(4):211-2. PubMed ID: 16761509
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Oral risperidone, olanzapine and quetiapine versus haloperidol in psychotic agitation.
    Villari V; Rocca P; Fonzo V; Montemagni C; Pandullo P; Bogetto F
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):405-13. PubMed ID: 17900775
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A randomized, flexible-dose, quasi-naturalistic comparison of quetiapine, risperidone, and olanzapine in the short-term treatment of schizophrenia: the QUERISOLA trial.
    Sacchetti E; Valsecchi P; Parrinello G;
    Schizophr Res; 2008 Jan; 98(1-3):55-65. PubMed ID: 17933497
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Metabolic adverse effects of olanzapine on cognitive dysfunction: A possible relationship between BDNF and TNF-alpha.
    Zhang C; Fang X; Yao P; Mao Y; Cai J; Zhang Y; Chen M; Fan W; Tang W; Song L
    Psychoneuroendocrinology; 2017 Jul; 81():138-143. PubMed ID: 28477447
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Adjunctive effects of aripiprazole on metabolic profiles: comparison of patients treated with olanzapine to patients treated with other atypical antipsychotic drugs.
    Wang LJ; Ree SC; Huang YS; Hsiao CC; Chen CK
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jan; 40():260-6. PubMed ID: 23085073
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of metabolic and prolactin variables from a six-month randomised trial of olanzapine and quetiapine in schizophrenia.
    Bushe C; Sniadecki J; Bradley AJ; Poole Hoffmann V
    J Psychopharmacol; 2010 Jul; 24(7):1001-9. PubMed ID: 19240085
    [TBL] [Abstract][Full Text] [Related]  

  • 60. High-density lipoprotein-cholesterol and antipsychotic medication in overweight inpatients with schizophrenia: post-hoc analysis of a Japanese nationwide survey.
    Ono S; Sugai T; Suzuki Y; Yamazaki M; Shimoda K; Mori T; Ozeki Y; Matsuda H; Sugawara N; Yasui-Furukori N; Okamoto K; Sagae T; Someya T
    BMC Psychiatry; 2018 Jun; 18(1):180. PubMed ID: 29879941
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.